Eurofins-Cerep

Delisting Announcement • Mar 19, 2010

Cerep's listing on NYSE Alternext Paris today

Paris, March 19, 2010 - press release 2010/04

Cerep SA [Nyse Alternext : ALCER] today announces the transfer of its shares from Euronext Paris to Alternext.

Cerep is a strategic partner of the pharmaceutical industry in the field of drug discovery. The Company has developed technologies and know how dedicated to a new drug discovery strategy. Cerep provides solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep technologies aim at determining rapidly and at low cost the pharmacological properties, metabolism and potential toxicity of drug candidates. Molecules are thus tested in vitro in a set of molecular and cellular models (or assays) developed and validated by Cerep. The results of in vitro profiles provide multiple indicators on the effects of the compounds in humans.

Cerep's listing was made under the direct listing procedure by admitting on Alternext the 12,611,875 existing shares representing the outstanding share capital of Cerep.

"Our presence at Euronext Paris imposed compliance with heavy and unsuited regulations compared to Cerep's situation, without providing specific advantages in terms of stock valuation or liquidity. In this way our shares transfer from one market to the other should simplify our company's running and reduce our structure costs. A listing on a market better fitting our group size should also improve our visibility", commented Thierry Jean, Président & CEO of Cerep.

Contact

Thierry Jean, Président-directeur général Sophie Macault, General Counsel & Corporate Secretary Tel. +33 (0)1 45 64 44 60 fincom@cerep.fr

Code ISIN FR0004042232 NYSE Alternext Paris

Cerep SA 155 boulevard Haussmann 75008 Paris (France) tel + 33(0)145 64 44 60 fax +33(0)145 64 44 64 e-mail: fincom@cerep.fr www.cerep.com

Focussing on in vitro pharmacology and ADME-Tox, Cerep [Nyse Alternext – ALCER] provides solutions allowing cost-effective drug discovery by identifying at early stages the most promising drug candidates and eliminating compounds likely to fail in development. Cerep's technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.